News | December 17, 2025
Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
GV20 received an upfront payment and is eligible for additional milestone payments
Subscribe To Our Newsletter & Stay Updated
